Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments

| April 20, 2015 | 0 Comments

by Steven T. Szabo, MD, PhD; Bruce J. Kinon, MD; Stephen K. Brannan, MD; Andrew K. Krystal, MD, MSc; Joop M A van Gerven, MD, PhD; Atul Mahableshwarkar, MD; and Gary S. Sachs, MD
Dr. Szabo is with Duke University Medical Center, Durham, North Carolina, and Veterans Administration Medical Center, Durham, North Carolina; Dr. Kinon is with Lundbeck LLC, Deerfield, Illinois (Dr. Kinon was with Eli Lilly and Company, Indianapolis, Indiana, when this material was presented); Dr. Brannan is with Takeda Global Research & Development Center, Inc., Deerfield, Illinois; Dr. Krystal is with Duke University Medical Center, Durham, North Carolina; Dr. van Gerven is with Centre for Human Drug Research, Leiden, The Netherlands; Dr. Mahableshwarkar is with Takeda Global Research & Development Center, Inc., Deerfield, Illinois; Dr. Sachs is with Massachusetts General Hospital, Boston, Massachusetts.

Innov Clin Neurosci 2015;12(3ā€“4 Suppl A):11Sā€“25S

The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Tags: , , , , , , ,

Category: Anxiety Disorders, Behavioral and Cognitive Neurology, Drug Development, Medical Issues, Mood Disorders, Neurology, Proceedings, Psychiatry, Psychopharmacology, Supplements, Trial Methodology

Leave a Reply